JP2005525345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525345A5 JP2005525345A5 JP2003569148A JP2003569148A JP2005525345A5 JP 2005525345 A5 JP2005525345 A5 JP 2005525345A5 JP 2003569148 A JP2003569148 A JP 2003569148A JP 2003569148 A JP2003569148 A JP 2003569148A JP 2005525345 A5 JP2005525345 A5 JP 2005525345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- saha
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 46
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 14
- 229960000237 vorinostat Drugs 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 150000007529 inorganic bases Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 150000007530 organic bases Chemical class 0.000 claims 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 150000001340 alkali metals Chemical class 0.000 claims 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 4
- 150000001342 alkaline earth metals Chemical class 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 claims 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 229960004919 procaine Drugs 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35738302P | 2002-02-15 | 2002-02-15 | |
| PCT/US2003/004924 WO2003070188A2 (en) | 2002-02-15 | 2003-02-14 | Method of treating trx mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525345A JP2005525345A (ja) | 2005-08-25 |
| JP2005525345A5 true JP2005525345A5 (enExample) | 2006-03-30 |
Family
ID=27757609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569148A Pending JP2005525345A (ja) | 2002-02-15 | 2003-02-14 | Ｔｒｘ媒介性疾患を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20030235588A1 (enExample) |
| EP (1) | EP1482962A4 (enExample) |
| JP (1) | JP2005525345A (enExample) |
| AU (1) | AU2003219803B8 (enExample) |
| CA (1) | CA2476434A1 (enExample) |
| WO (1) | WO2003070188A2 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0014254A (pt) * | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| WO2002060933A2 (en) * | 2001-01-30 | 2002-08-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeht | Thioredoxin derived from h. pylori, which is capable of inhibiting nf-kappa b activation |
| EP1443928B1 (en) * | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| MXPA04008577A (es) * | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| WO2003083067A2 (en) * | 2002-03-28 | 2003-10-09 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| US8946295B2 (en) * | 2002-07-25 | 2015-02-03 | Sunny Pharmtech Inc. | Histone hyperacetylating agents for promoting wound healing and preventing scar formation |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2004228011A1 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| HRP20060080A2 (en) * | 2003-08-26 | 2006-07-31 | Sloan-Kettering Institute For Cancer Research | Method of treating cancer with hdac inhibitors |
| CN102349927A (zh) * | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| AU2004280264A1 (en) * | 2003-10-09 | 2005-04-21 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
| CN1905881A (zh) * | 2003-11-26 | 2007-01-31 | 阿托恩药品公司 | 二胺和亚氨二醋酸异羟肟酸衍生物 |
| US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
| US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| CA2561617A1 (en) * | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| WO2005117930A2 (en) * | 2004-06-04 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Use of thioredoxin measurements for diagnostics and treatments |
| US7132454B2 (en) * | 2004-08-27 | 2006-11-07 | Regents Of The University Of California | HEXIM1 as a suppressor of HIV replication and cardiac hypertrophy |
| US8889742B2 (en) * | 2004-11-30 | 2014-11-18 | The Trustees Of The University Of Pennsylvania | Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury |
| CA2591443A1 (en) * | 2004-12-14 | 2006-06-22 | Biorunx Co. Ltd. | Method to enhance the bone formation activity of bmp by runx2 acetylation |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2110667A1 (en) * | 2005-01-20 | 2009-10-21 | University Of Rochester | Thoredoxin interacting protein (TXNIP) as regulator of vascular function |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| JP2008530136A (ja) * | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| WO2006090849A1 (ja) * | 2005-02-25 | 2006-08-31 | Redox Bioscience Inc. | 炎症性眼表面疾患の予防ないし治療剤 |
| EP1719543A1 (en) * | 2005-05-04 | 2006-11-08 | Asan Labs., Ltd. | Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| SI1901729T1 (sl) * | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| CA2617636A1 (en) * | 2005-08-10 | 2007-02-22 | Novartis Ag | Use of histone deacetylase inhibitors for treating cardiac hypertrophy and heart failure |
| EP1940379A4 (en) * | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
| CA2627129A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| JP2009514879A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法 |
| CA2622136A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| CA2667348A1 (en) * | 2006-11-03 | 2008-05-15 | University Of Maryland, Baltimore | Methods of using saha and bortezomib for treating multiple myeloma |
| US8088951B2 (en) * | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| EP2102230A2 (en) | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Purifiction of romidepsin |
| WO2008088331A1 (en) * | 2007-01-19 | 2008-07-24 | Gloucester Pharmaceuticals | Methods for increasing levels of human fetal hemoglobin |
| US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| US20100093611A1 (en) * | 2007-05-16 | 2010-04-15 | Horrigan Stephen K | Compounds and methods for treating or preventing autoimmune diseases |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US9526707B2 (en) | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
| CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| JP2010540630A (ja) * | 2007-10-04 | 2010-12-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのｎ−ヒドロキシ−ナフタレンジカルボキサミド及びｎ−ヒドロキシ−ビフェニル−ジカルボキサミド化合物 |
| SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
| ES2332687B1 (es) * | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| JP2012500283A (ja) * | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク． | （ｒ）−プラミペキソールを使用した組成物並びにその方法 |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2011053876A1 (en) * | 2009-10-30 | 2011-05-05 | Massachusetts Institute Of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| CN103108648A (zh) | 2010-07-12 | 2013-05-15 | 细胞基因公司 | 罗米地辛固体形式及其用途 |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| WO2013041407A1 (en) * | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US20160281133A1 (en) * | 2013-03-18 | 2016-09-29 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
| RS67279B1 (sr) | 2013-07-12 | 2025-10-31 | Areteia Therapeutics Inc | Lečenje povišenih nivoa eozinofila i/ili bazofila |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| EP3033081B1 (en) | 2013-08-13 | 2021-05-12 | Knopp Biosciences LLC | Compositions and methods for treating chronic urticaria |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN104490854A (zh) * | 2014-12-27 | 2015-04-08 | 中国人民解放军第四军医大学 | 丁酸钠的治疗变态反应性鼻炎的应用 |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| CN107698464A (zh) * | 2017-10-12 | 2018-02-16 | 江苏师范大学 | 具有组蛋白去乙酰化酶抑制作用的贝利司他结构类似物及其应用 |
| KR102187148B1 (ko) * | 2018-08-20 | 2020-12-04 | 주식회사 휴젝스 | 산발적 파킨슨병 진단의 정보제공방법 및 약물 스크리닝 방법 |
| CN110790686B (zh) * | 2019-10-08 | 2022-03-08 | 南开大学 | 一种化合物及其在制备抗炎以及治疗急性肺损伤、慢阻肺、哮喘或肺纤维化药物中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5330744A (en) * | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
| US5098899A (en) * | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
| US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5724983A (en) * | 1994-08-01 | 1998-03-10 | New England Center Hospitals, Inc. | Continuous monitoring using a predictive instrument |
| EP0827742A1 (en) * | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| WO2000021979A2 (en) * | 1998-10-13 | 2000-04-20 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| EP1123111B1 (en) * | 1998-10-19 | 2004-09-15 | Methylgene, Inc. | Modulation of dna methyltransferase expression by combination therapy |
| BR0014254A (pt) * | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| WO2002022133A1 (en) * | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| GB0023983D0 (en) * | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002102323A2 (en) * | 2001-06-14 | 2002-12-27 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| MXPA04008577A (es) * | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| JP2006508986A (ja) * | 2002-11-20 | 2006-03-16 | エルラント ゲネ セラペウチクス エルエルシー | ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法 |
| AU2004228011A1 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
-
2003
- 2003-02-14 US US10/369,094 patent/US20030235588A1/en not_active Abandoned
- 2003-02-14 WO PCT/US2003/004924 patent/WO2003070188A2/en not_active Ceased
- 2003-02-14 JP JP2003569148A patent/JP2005525345A/ja active Pending
- 2003-02-14 CA CA002476434A patent/CA2476434A1/en not_active Abandoned
- 2003-02-14 EP EP03716078A patent/EP1482962A4/en not_active Withdrawn
- 2003-02-14 AU AU2003219803A patent/AU2003219803B8/en not_active Ceased
-
2005
- 2005-09-09 US US11/223,405 patent/US20060009526A1/en not_active Abandoned
- 2005-09-09 US US11/223,547 patent/US20060009527A1/en not_active Abandoned